Skip to content
Peptigraph home

PT-141 for Libido: What the Evidence Shows

What human and animal studies show about PT-141 for libido, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureMelanocortin agonistUpdated
Strongest evidence
Human RCT
Human studies
8
PubMed records, our ledger
Animal studies
1
PubMed records, our ledger
Studies we summarised
9
with an outcome for libido

Evidence for libido

Each row is an outcome related to libido from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

PT-141 for libido: outcomes in published studies
OutcomeResultStudy typeSource
Desire and distress across subgroupsBenefit on desire and distress was seen across age, weight and BMI subgroups.Human RCTn = 1202Journal of women's health 2022, PMID 35230162
Patient-reported experienceExit surveys and interviews: bremelanotide users described more desire, arousal and better sexual activity quality.Human RCTn = 242Journal of women's health 2021, PMID 33538638
Sexual desire (FSFI-desire domain)Desire domain score rose more than placebo: 0.30 (study 301), 0.42 (study 302), 0.35 integrated, all P<.001.Human RCTn = 1267Obstetrics and gynecology 2019, PMID 31599840
Distress related to low desireDistress fell more than placebo: -0.37, -0.29 and -0.33 integrated.Human RCTn = 1267Obstetrics and gynecology 2019, PMID 31599840
Responder ratesAt 1.75 mg, responder rates beat placebo on all 7 endpoints (P ≤ .03).Human RCTThe journal of sexual medicine 2019, PMID 31277966
Satisfying sexual events+0.7 versus +0.2 satisfying sexual events per month (p = 0.0180).Human RCTn = 327Women's health 2016, PMID 27181790
Positive clinical response in sildenafil non-responders51 (33.5%) of the bremelanotide group had positive clinical results versus 13 (8.5%) on placebo (p = 0.03).Human RCTn = 342The Journal of urology 2008, PMID 18206919
Sexual desireMore women reported moderate or high desire after bremelanotide than placebo (P = 0.0114).Human RCTn = 18The journal of sexual medicine 2006, PMID 16839319
Vaginal vasocongestionNo significant change in vaginal vasocongestion versus placebo.Human RCTn = 18The journal of sexual medicine 2006, PMID 16839319
Erectile response (RigiScan)Erectile response was statistically significant versus placebo at both 4 mg and 6 mg in men with inadequate response to Viagra.Human RCTInternational journal of impotence research 2004, PMID 14999221
Erectile response (RigiScan)Erectile response beat placebo at doses above 7 mg; first erection began in about 30 minutes.Human RCTInternational journal of impotence research 2004, PMID 14963471

PubMed records for PT-141 and libido: 8 human, 1 animal (search counts, not studies we reviewed). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4Journal of women's health 2022, PMID 35230162

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Erectile dysfunction versus low desire

MedlinePlus defines erectile dysfunction as a man having trouble getting or keeping an erection.[10]

It lists lack of sexual desire, inability to become aroused, lack of orgasm and painful intercourse as the problems that can keep a woman from enjoying sex.[11]

What the FDA-approved version is and is not for

Vyleesi, the approved bremelanotide product, is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder.[12]

Its label says it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance.[12]

The erectile dysfunction trials that were run

A randomized trial in men whose sildenafil had failed gave intranasal bremelanotide, with positive clinical results in 33.5% against 8.5% on placebo.[6]

That trial also reported more drug-related adverse effects on bremelanotide.[6]

In a crossover trial in men with ED, an erectile response to PT-141 4 mg or 6 mg was statistically significant versus placebo.[8]

A separate PT-141 study reported a statistically significant erectile response versus placebo at doses greater than 7 mg, with the first erection starting in approximately 30 min.[9]

Desire trials in women

In studies 301 and 302, women taking bremelanotide had statistically significant increases in sexual desire scores compared with placebo.[3]

Label safety information

The label reports nausea in 40% of patients who received up to 8 monthly doses, with 8% stopping early.[12]

The label contraindicates it in patients with uncontrolled hypertension or known cardiovascular disease.[12]

The label advises patients to discontinue it if pregnancy is suspected.[12]

Other peptides people research for libido

Common questions

Does PT-141 help with libido?

The strongest study we summarise for libido is human rct evidence, across 9 studies with an outcome for libido. A trial result is not an approval; see the legal status.

Is PT-141 approved for libido?

PT-141 is FDA approved for HSDD (Vyleesi). Which conditions that approval covers is set by the label; use for anything else is off-label.

Does PT-141 work for erectile dysfunction?

In men whose sildenafil had failed, intranasal bremelanotide gave positive clinical results in 33.5% against 8.5% on placebo; that is a trial result, not an approved use.[6]

Is PT-141 FDA approved for libido?

The approved form is Vyleesi, for premenopausal women with HSDD. Its label says it is not indicated in men or to enhance sexual performance.[12]

What are the side effects of PT-141?

In the label's data nausea was reported by 40% of patients, requiring anti-emetic therapy in 13%.[12]

More on PT-141

Sources

  1. 1Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  2. 2The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.Journal of women's health (2002) · 2021PMID 33538638Accessed 2 Oct 2026
  3. 3Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
  4. 4Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
  5. 5Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Women's health (London, England) · 2016PMID 27181790Accessed 2 Oct 2026
  6. 6Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
  7. 7An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.The journal of sexual medicine · 2006PMID 16839319Accessed 2 Oct 2026
  8. 8Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.International journal of impotence research · 2004PMID 14999221Accessed 2 Oct 2026
  9. 9Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.International journal of impotence research · 2004PMID 14963471Accessed 2 Oct 2026
  10. 10Official web pageOfficial web page · web page
  11. 11medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  12. 12VYLEESI prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.